Role of serum cholesterol in Parkinson's disease: A meta-analysis of evidence

Journal of Parkinson's Disease

Volumn 3, Issue 3, 2013, Pages 363-370

  Gudala, Kapil ^a   Bansal, Dipika ^a   Muthyala, Harini ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Meta analysis; Parkinson's disease; Serum cholesterol

Indexed keywords

CHOLESTEROL;

ARTICLE; CAUSAL ATTRIBUTION; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; HUMAN; LIPID ANALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHOLESTEROL; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PUBLICATION BIAS; RISK;

EID: 84888872037     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130196     Document Type: Article

References (32)

1. Tanner CM, & Goldman SM (1996) Epidemiology of Parkinson's disease. Neurologic Clinics, 14, 317-335
2. Sohmiya M, Tanaka M, Tak NW, Yanagisawa M, Tanino Y, Suzuki Y, Okamoto K, & Yamamoto Y (2004) Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. Journal of the Neurological Sciences, 223, 161-166
3. Zhou C, Huang Y, & Przedborski S (2008) Oxidative stress in Parkinson's disease. Annals of the New York Academy of Sciences, 1147, 93-104
4. Huang X, Abbott RD, Petrovitch H, Mailman RB,&RossGW (2008) LowLDLcholesterol and increased risk of Parkinson's disease: Prospective results from Honolulu-Asia Aging Study. Movement Disorders, 23, 1013-1018
5. Liu JP, Tang Y, Zhou S, Toh BH, McLean C, & Li H (2010) Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Molecular and Cellular Neuroscience, 43, 33-42
6. Reiss AB, Siller KA, Rahman MM, Chan ES, Ghiso J, & de Leon MJ (2004) Cholesterol in neurologic disorders of the elderly: Stroke and Alzheimer's disease. Neurobiology of Aging, 25, 977-989
7. Anstey KJ, Lipnicki DM, & Low LF (2008) Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-Analysis. American Journal of Geriatric Psychology, 16, 343-354
8. Grandinetti A, Morens DM, Reed D,&MacEachern D (1994) Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease American Journal of Epidemiology, 139, 1129-1138
9. de Lau LM, Koudstaal PJ, Hofman A, & BretelerM M (2006) Serum cholesterol levels and the risk of Parkinson's disease. American Journal of Epidemiology, 164, 998-1002
10. Simon KC, Chen H, Schwarzschild M, & Ascherio A (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology, 69, 1688-1695
11. Hu G, Antikainen R, Jousilahti P, Kivipelto M, & Tuomilehto J (2008) Total cholesterol and the risk of Parkinson disease. Neurology, 70, 1972-1979
12. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G,& Girotti F (2006) Reduced risk factors for vascular disorders in parkinson disease patients: A case-control study. Stroke, 37, 1184-1188
13. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, & Poole C (2007) Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease.Movement Disorders, 22, 377-381
14. Becker C, Jick SS, & Meier CR (2008) Use of antihypertensives and the risk of Parkinson disease Neurology, 70, 1438-1444
15. Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, & Nagai M (2010) Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. Journal of the Neurological Sciences, 293, 82-86
16. Miyake Y, Sasaki S, Tanaka K, Fukushima W, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, & Nagai M (2010) Dietary fat intake and risk of Parkinson's disease: A case-control study in Japan. Journal of the Neurological Sciences, 288, 117-122
17. Chen H, Zhang SM, Hern'an MA, Willett WC, & Ascherio A (2003) Dietary intakes of fat and risk of Parkinson's disease American Journal of Epidemiology, 157, 1007-1014
18. de Lau LM, Bornebroek M, Witteman JC, Hofman A, Koudstaal PJ, & Breteler MM (2005) Dietary fatty acids and the risk of Parkinson disease. The Rotterdam Study. Neurology, 64, 2040-2045
19. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD,&Checkoway H (2009) Dietary fats, cholesterol and iron as risk factors for Parkinson's disease. Parkinsonism & Related Disorders, 15, 47-52
20. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-Analyses, http://www.ohri.ca/programs/clinical epidemiology/oxford.asp, Accessed on 22 January 2013
21. Song F, Sheldon TA, Sutton AJ, Abrams KR, & Jones DR (2001) Methods for exploring heterogeneity in meta-Analysis. Evaluation and The Health Professions, 24, 126-151
22. Egger M, Smith GD, & Phillips AN (1997) Meta-Analysis: Principles and procedures. British Medical Journal, 315, 1533-1537
23. Jimenez-Jimenez FJ, Molina JA, De Bustos F, Garc'ia-Redondo A, G'omez-Escalonilla C, Mart'inez-Salio A, & Berbel A (2000) Serum levels of coenzyme Q 10 in patients with Parkinson's disease Journal of Neural Transmission, 107, 177-181
24. Kaikkonen J, Nyyssönen K, Tuomainen TP, Ristonmaa U, & Salonen JT (1999) Determinants of plasma coenzyme Q10 in humans. FEBS Letters, 443, 163-166
25. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, & Lew M (2002) Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Archives of Neurology, 59, 1541-1550
26. Beal MF, Matthews RT, Tieleman A, & Shults CW (1998) Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-Tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice Brain Research, 783, 109-114
27. Bar-On P, Rockenstein E, Adame A, Ho G, Hashimoto M, & Masliah E (2006) Effects of the cholesterollowering compound methyl-ß-cyclodextrin in models of a-synucleinopathy. Journal of Neurochemistry, 98, 1032-1045
28. Barcelo-Coblijn G, Golovko MY, Weinhofer I, Berger J, & Murphy EJ (2007) Brain neutral lipids mass is increased in alpha-synuclein gene-Ablated mice. Journal of Neurochemistry, 101, 132-141
29. Chen H, Zhang SM, Schwarzschild MA, Hern'an MA, & Ascherio A (2005) Physical activity and the risk of Parkinson disease. Neurology, 64, 664-669
30. Musanti R, Parati E, Lamperti E, & Ghiselli G (1993) Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease. Biochemical Medicine and Metabolic Biology, 49, 133-142
31. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, Soininen H, & Kivipelto M (2007) Serum cholesterol changes after midlife and late-life cognition: Twenty-one-year follow-up study. Neurology, 68, 751-756
32. Undela K, Gudala K, Malla S, & Bansal D (2012) Statin use and risk of Parkinson's disease: A meta-Analysis of observational studies. Journal of Neurology, 260, 158-165